Association of anti‐IL‐12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events

Abstract

Journal of the European Academy of Dermatology and VenereologyVolume 27, Issue 12 p. 1586-1587 Letter to the Editor Association of anti-IL-12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events T. Tzellos, T. Tzellos Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany Department of Pharmacology and Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorA. Kyrgidis, A. Kyrgidis Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany Department of Pharmacology and Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorA. Trigoni, A. Trigoni State Clinic, Hospital for Skin and Venereal Diseases, Thessaloniki, GreeceSearch for more papers by this authorC.C. Zouboulis, Corresponding Author C.C. Zouboulis Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany Correspondence: C.C. Zouboulis. E-mail:christos.zouboulis@klinikum-dessau.deSearch for more papers by this author T. Tzellos, T. Tzellos Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany Department of Pharmacology and Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorA. Kyrgidis, A. Kyrgidis Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany Department of Pharmacology and Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorA. Trigoni, A. Trigoni State Clinic, Hospital for Skin and Venereal Diseases, Thessaloniki, GreeceSearch for more papers by this authorC.C. Zouboulis, Corresponding Author C.C. Zouboulis Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany Correspondence: C.C. Zouboulis. E-mail:christos.zouboulis@klinikum-dessau.deSearch for more papers by this author First published: 06 March 2013 https://doi.org/10.1111/jdv.12126Citations: 12Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume27, Issue12December 2013Pages 1586-1587 RelatedInformation